Pfizer Sees Marginal Slump In Performance

Pfizer has attributed its poor Q209 sales and profit figures to unfavourable foreign exchange rates. While this is technically correct, analysis of the firm's financial statement reveals a concerning piece of information - revenue in the US decreased by 5% compared to the same period in the previous year. While some of the decline can be blamed on patent expiries and other factors, it is clear to BMI that the economic downturn is impacting pharmaceutical firms more than previously

To read the full article, please choose one of the following options: